Patients Coming Off Anti-Obesity Medications Regain Weight Far More Rapidly Than People Using Diet and Exercise
Fresh analysis reveals that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop conventional lifestyle regimens.
Research printed in a prominent health publication points out that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month after stopping.
"Users buying these treatments should be aware of the potential of rapid rebound weight gain when the medication concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to original weight within about a year and a half.
Analyzing Therapies
The analysis, which examined dozens of studies involving over 9,000 of participants, compared the effects of GLP-1 agonists with conventional dieting.
The team emphasize that individuals who lose weight through lifestyle changes alone typically have a slower weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Rapid Regain
Nutrition scientists suggest the mode of action of the injections explains the amplified regain.
The injections copy a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than the body's typical production could lead to the body to produce less of its endogenous GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in appetite is no longer kept in check, making binge eating much more probable."
An Ongoing Disease?
The NHS recommend the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications.
A number of clinicians contend that, due to the likelihood of relapse, the therapy might need to be ongoing.
This view is reinforced by pharmaceutical companies, who note that the findings "highlight the chronic character of excess weight," comparing it to managing diseases like diabetes.
User Accounts
Users who have come off the jabs explain a intense return of cravings.
"It was like something that goes on and you're instantly starving," described an individual.
This challenge is compounded if individuals have not established sustainable dietary or behavioural modifications during treatment.
Widespread Interest
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Adoption is greater among women than men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while the jabs are potent agents for shedding pounds, they are not a standalone solution and lasting health benefits hinges on ongoing behavioural support.
